IL130993A0 - Biocompatible compounds for pharmaceutical drug delivery systems - Google Patents

Biocompatible compounds for pharmaceutical drug delivery systems

Info

Publication number
IL130993A0
IL130993A0 IL13099398A IL13099398A IL130993A0 IL 130993 A0 IL130993 A0 IL 130993A0 IL 13099398 A IL13099398 A IL 13099398A IL 13099398 A IL13099398 A IL 13099398A IL 130993 A0 IL130993 A0 IL 130993A0
Authority
IL
Israel
Prior art keywords
formulation
sustained release
biocompatible polymer
drug
drug delivery
Prior art date
Application number
IL13099398A
Other languages
English (en)
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of IL130993A0 publication Critical patent/IL130993A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IL13099398A 1997-02-07 1998-02-04 Biocompatible compounds for pharmaceutical drug delivery systems IL130993A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,803 US6126919A (en) 1997-02-07 1997-02-07 Biocompatible compounds for pharmaceutical drug delivery systems
PCT/US1998/000074 WO1998034596A2 (en) 1997-02-07 1998-02-04 Biocompatible compounds for pharmaceutical drug delivery systems

Publications (1)

Publication Number Publication Date
IL130993A0 true IL130993A0 (en) 2001-01-28

Family

ID=25171845

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13099398A IL130993A0 (en) 1997-02-07 1998-02-04 Biocompatible compounds for pharmaceutical drug delivery systems

Country Status (15)

Country Link
US (3) US6126919A (xx)
EP (2) EP1014944B1 (xx)
JP (1) JP2001511179A (xx)
KR (1) KR100564130B1 (xx)
CN (1) CN1114400C (xx)
AT (1) ATE359062T1 (xx)
AU (1) AU724765B2 (xx)
CA (1) CA2279522C (xx)
DE (1) DE69837549T2 (xx)
HK (1) HK1030357A1 (xx)
HU (1) HUP0001914A3 (xx)
IL (1) IL130993A0 (xx)
NZ (1) NZ336903A (xx)
PL (1) PL196261B1 (xx)
WO (1) WO1998034596A2 (xx)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6319521B1 (en) * 1999-02-10 2001-11-20 University Technology Corporation Microparticles of lactide-co-glycolide copolymers and methods of making and using the same
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
HUP0201626A3 (en) * 1999-06-04 2004-05-28 Alza Corp Mountain View Implantable gel compositions and method of manufacture
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
CA2393776C (en) * 1999-12-15 2009-02-10 Sulzer Orthopedics Ltd. Preparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
DZ3358A1 (fr) 2000-05-22 2001-11-29 Chiesi Farma Spa Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
AU2001281746C1 (en) 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
DE10058829B4 (de) * 2000-11-27 2004-08-26 3M Espe Ag Verwendung von Polysäuren mit enger Molmassenverteilung
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002092154A1 (en) 2001-04-26 2002-11-21 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
DK1273292T3 (da) 2001-07-02 2004-10-04 Chiesi Farma Spa Optimeret tobramycinformulering til aerosoldannelse
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
WO2003037317A1 (en) * 2001-10-26 2003-05-08 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
DE60231428D1 (de) * 2001-12-21 2009-04-16 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
US20030147814A1 (en) * 2001-12-21 2003-08-07 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
ATE406152T1 (de) * 2001-12-21 2008-09-15 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
EP1340503A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
JP2005523905A (ja) 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7947742B2 (en) * 2002-06-28 2011-05-24 Civitas Therapeutics, Inc. Inhalable epinephrine
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
UA84276C2 (uk) * 2002-08-27 2008-10-10 Хіроші Терада Лікарський засіб проти туберкульозу
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
KR20050105490A (ko) * 2003-02-26 2005-11-04 오츠카 세이야쿠 가부시키가이샤 경폐 투여용 서방성 제제학적 조성물
WO2004087777A2 (en) * 2003-03-28 2004-10-14 Carnegie Mellon University Degradable polymers
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
FR2854071B1 (fr) * 2003-04-25 2009-01-30 Ethypharm Sa Procede de dispersion de substances hydrosolubles ou hydrophiles dans un fluide a pression supercritique
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1699847B1 (en) * 2003-12-30 2011-04-13 3M Innovative Properties Company Method for the preparation of medicinal compositions
US20050271597A1 (en) * 2004-02-13 2005-12-08 Keith Alec D Prostate hypertrophy treatment composition and method
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
JP5171248B2 (ja) 2004-03-05 2013-03-27 カーネギー−メロン ユニバーシティ 原子移動ラジカル重合法
EP1732527A2 (en) * 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
ES2602273T3 (es) 2004-09-17 2017-02-20 Durect Corporation Composición anestésica local prolongada que contiene Saib
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
MX2007003468A (es) * 2004-09-24 2007-05-18 3M Innovative Properties Co Formulaciones medicinales en aerosol y metodos de sintesis de los ingredientes para las mismas.
MX2007011161A (es) * 2005-03-14 2007-11-13 3M Innovative Properties Co Compuestos polimericos biocompatibles para formulaciones medicinales.
EP1883665B1 (en) 2005-04-22 2017-10-11 Universite De Geneve Polylactide compositions and uses thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
WO2007025086A2 (en) 2005-08-23 2007-03-01 Carnegie Mellon University Atom transfer radical polymerization in microemulsion and true emulsion polymerization
CN101379091B (zh) 2005-08-26 2012-05-30 卡内基梅隆大学 在催化剂再生下的聚合方法
US20070196416A1 (en) 2006-01-18 2007-08-23 Quest Pharmaceutical Services Pharmaceutical compositions with enhanced stability
US20090123391A1 (en) * 2006-03-22 2009-05-14 3M Innovative Properties Company Novel Formulations
US7943651B2 (en) 2006-04-20 2011-05-17 Glaxo Group Limited Compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US8580307B2 (en) * 2006-06-22 2013-11-12 Ethicon, Inc. High glass transition temperature absorbable microspheres
JP2009545579A (ja) 2006-08-01 2009-12-24 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物、及びｐｄｅ４阻害薬としてのその使用
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US8367051B2 (en) 2006-10-09 2013-02-05 Carnegie Mellon University Preparation of functional gel particles with a dual crosslink network
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008148000A1 (en) 2007-05-23 2008-12-04 Carnegie Mellon University Atom transfer dispersion polymerization
WO2009023353A1 (en) 2007-05-23 2009-02-19 Carnegie Mellon University Hybrid particle composite structures with reduced scattering
WO2008152398A2 (en) * 2007-06-14 2008-12-18 Cipla Limited Formulations for inhalation
WO2009052519A2 (en) * 2007-10-19 2009-04-23 Wayne State University Co-polymer stabilizers for hydrofluoroalkane dispersions
JP2011503183A (ja) * 2007-11-13 2011-01-27 サーモディクス ファーマシューティカルズ， インコーポレイテッド 薬物送達のプラットホームとしての粘稠なターポリマー
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US7979151B2 (en) * 2007-12-06 2011-07-12 International Business Machines Corporation Run-time dispatch system for enhanced product characterization capability
CN101896169B (zh) * 2007-12-12 2012-11-14 巴斯夫欧洲公司 具有聚合物抗衡离子的活性成分的盐
US9308162B2 (en) * 2008-06-03 2016-04-12 Tolmar Therapeutics, Inc. Biocompatible oligomer-polymer compositions
US8927617B2 (en) 2008-06-30 2015-01-06 Kimberly-Clark Worldwide, Inc. Fragranced water-sensitive film
US8759279B2 (en) * 2008-06-30 2014-06-24 Kimberly-Clark Worldwide, Inc. Fragranced biodegradable film
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
EP3246030A1 (en) 2008-08-11 2017-11-22 GlaxoSmithKline LLC Novel adenine derivatives
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EA201171144A1 (ru) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
GB2481561B (en) 2009-03-27 2013-12-11 Univ Carnegie Mellon Preparation of functional star macromolecules
EP2411516A1 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
CA2756072A1 (en) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
DK2501363T3 (en) 2009-11-17 2015-03-23 Cipla Ltd inhalable
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
US8703754B2 (en) 2010-02-10 2014-04-22 Glaxosmithkline Llc 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012030822A1 (en) 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Process for reducing moisture in a biodegradable implant device
US9113916B2 (en) 2010-08-31 2015-08-25 Zimmer, Inc. Drill bit for osteochondral drilling with guiding element and uses thereof
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012091965A1 (en) 2010-12-17 2012-07-05 Carnegie Mellon University Electrochemically mediated atom transfer radical polymerization
CA2838030A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
EP2747753B1 (en) 2011-08-22 2023-03-29 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
EP2773324A4 (en) * 2011-11-03 2015-07-01 Prec Dermatology Inc STABLE DERMATOLOGICAL AEROSOL FOAMS USING REACTIVE PROPELLERS
WO2013126745A2 (en) 2012-02-23 2013-08-29 Carnegie Mellon University Ligands designed to provide highly active catalyst complexes
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
MX2015016102A (es) 2013-05-23 2016-08-08 Aztherapies Inc Metodos para la liberacion de cromolina.
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
SI3104854T1 (sl) 2014-02-10 2020-09-30 Respivant Sciences Gmbh Stabilizatorji mastocitov za zdravljenje pljučnih bolezni
CN106456595A (zh) 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于***性病症的肥大细胞稳定剂治疗
JP6452711B2 (ja) 2014-02-20 2019-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体
US9968758B2 (en) * 2014-03-21 2018-05-15 Boston Scientific Scimed, Inc. Devices and methods for treating a lung
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
ES2917887T3 (es) 2014-11-13 2022-07-12 Glaxosmithkline Biologicals Sa Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
JP2018535984A (ja) 2015-11-18 2018-12-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ リバビリンの医薬組成物
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
AR107044A1 (es) 2015-12-17 2018-03-14 Astex Therapeutics Ltd Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararla
AU2017321782B2 (en) 2016-08-31 2022-03-10 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
WO2018132582A1 (en) 2017-01-12 2018-07-19 Carnegie Mellon University Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
EP3654946A4 (en) 2017-07-20 2021-04-21 AZTherapies, Inc. POWDER FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFEN
EP3743041A1 (en) 2018-01-26 2020-12-02 Apidel SA New spironolactone formulations and their use
AU2019289228A1 (en) 2018-06-22 2021-01-21 Ucl Business Ltd Novel compounds
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457238A (en) * 1948-12-28 Fractionation of polymeric
US3079299A (en) * 1959-11-16 1963-02-26 Gen Aerosol Corp Self-propelling medicinal ointment composition containing polyethylene and method ofapplication
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3933825A (en) * 1973-05-14 1976-01-20 Bristol-Myers Company Amine salts of acyl lactylic acids
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
CH660488A5 (en) 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
US5236702A (en) * 1983-02-28 1993-08-17 Henkel Kommanditgesellschaft Auf Aktien Composition and method for blood coagulation on hard body tissues
US4670250A (en) * 1983-10-21 1987-06-02 Bend Research, Inc. Durable controlled release microcapsules
GB8504629D0 (en) * 1984-03-21 1985-03-27 Ici Plc Surfactant
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
CA1293929C (en) * 1986-03-10 1992-01-07 Kurt Burghart Pharmaceutical composition containing nifedipine
DE3616020A1 (de) * 1986-05-13 1987-11-19 Opel Adam Ag Verriegelungsmechanismus fuer den handschuhkastendeckel eines fahrzeuges
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
DE3620685A1 (de) * 1986-06-20 1987-12-23 Henkel Kgaa Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
EP0261572A1 (de) 1986-09-20 1988-03-30 Boehringer Ingelheim Kg Verfahren zur Herstellung von Lactid
US4851211A (en) * 1986-11-25 1989-07-25 Abbott Laboratories LHRH analog formulations
JPH01503281A (ja) * 1987-05-27 1989-11-09 ブルグハルト，クルト 経皮治療に有効な医薬包帯剤およびこれを施用するためのデバイス
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4981850A (en) * 1988-02-05 1991-01-01 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimido[1,4]azines as bronchodilators
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DE3825211A1 (de) * 1988-07-25 1990-02-01 Henkel Kgaa Verbesserte koerperresorbierbare knochenwachse (iii)
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
JP2714454B2 (ja) 1988-11-07 1998-02-16 三井東圧化学株式会社 生体吸収性ポリエステルの製造方法
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE3916020C2 (de) 1989-05-17 1994-06-01 Burkhard Dr Wichert Retardierende Mikropartikel aus bioabbaubaren Polyestern; Verfahren zu deren Herstellung unter Verzicht auf toxische Lösungsmittel und diese Mikropartikel enthaltende pharmazentische Zubereitungen
DE3917617A1 (de) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JPH04226125A (ja) 1990-06-23 1992-08-14 Boehringer Ingelheim Kg ポリ−ｄ，ｌ−ラクチドの製造方法及び活性物質の担体としてのそれらの使用
EP0463194A1 (de) 1990-06-23 1992-01-02 Boehringer Ingelheim Kg Verfahren zur Herstellung von Poly-(D,L-lactid) und seine Verwendung als Wirkstoffträger
CA2054909A1 (en) * 1990-12-06 1992-06-07 Maciej Radosz Supercritical mixed-solvent separation of polymer mixtures
SE9100610D0 (sv) * 1991-03-04 1991-03-04 Procordia Ortech Ab Bioresorbable material for medical use
FR2673843B1 (fr) * 1991-03-14 1995-01-13 Centre Nat Rech Scient Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
TW247878B (xx) * 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
KR100291620B1 (ko) * 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
ATE175132T1 (de) * 1992-10-26 1999-01-15 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung von mikrokapseln
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0678018B1 (en) * 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ES2122261T3 (es) * 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
ES2107203T3 (es) * 1993-03-17 1997-11-16 Minnesota Mining & Mfg Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido.
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JP3220331B2 (ja) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
CA2166469C (en) * 1993-08-13 2002-03-26 Paul Anthony Bowser Cosmetic composition containing hydroxy alkanoate derivatives
JP3339600B2 (ja) 1994-05-23 2002-10-28 東洋紡績株式会社 ポリ乳酸及び／又はその共重合体
JP3367577B2 (ja) 1994-05-24 2003-01-14 東洋紡績株式会社 酸末端封鎖ポリ乳酸
US5618911A (en) * 1993-08-19 1997-04-08 Toyo Boseki Kabushiki Kaisha Polymer containing lactic acid as its constituting unit and method for producing the same
ATE233544T1 (de) * 1993-12-02 2003-03-15 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
ATE178789T1 (de) * 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
JP3524195B2 (ja) 1994-02-21 2004-05-10 武田薬品工業株式会社 徐放性製剤用基剤
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
JPH10503771A (ja) * 1994-08-04 1998-04-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー 尿素誘導体でのロイコトリエン生合成の阻害
US5478921A (en) * 1994-08-25 1995-12-26 United States Surgical Corporation Method of purifying bioabsorable polymer
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
EP0727711A3 (en) * 1995-02-17 1997-04-09 Ocg Microelectronic Materials Photoresist compositions containing supercritical fluid fractionated polymeric resin binders
US5618850A (en) * 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5633022A (en) 1995-06-08 1997-05-27 Old Line Plastics, Inc. Differential temperature vacuum-forming tool
JPH0959218A (ja) 1995-08-25 1997-03-04 Shimadzu Corp Ｌ−乳酸オリゴマー誘導体
JPH09124778A (ja) 1995-10-31 1997-05-13 Shimadzu Corp ポリ乳酸の製造法
AU727340C (en) * 1996-04-23 2001-11-08 Ipsen Manufacturing Ireland Limited Acidic polylactic polymers
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems

Also Published As

Publication number Publication date
CN1114400C (zh) 2003-07-16
PL335020A1 (en) 2000-03-27
EP1014944B1 (en) 2007-04-11
ATE359062T1 (de) 2007-05-15
HK1030357A1 (en) 2001-05-04
NZ336903A (en) 2001-08-31
DE69837549T2 (de) 2007-12-20
CA2279522A1 (en) 1998-08-13
CA2279522C (en) 2008-01-15
US6416742B1 (en) 2002-07-09
US6126919A (en) 2000-10-03
CN1246790A (zh) 2000-03-08
WO1998034596A2 (en) 1998-08-13
PL196261B1 (pl) 2007-12-31
US7687054B2 (en) 2010-03-30
WO1998034596A3 (en) 1998-11-05
AU6238498A (en) 1998-08-26
DE69837549D1 (de) 2007-05-24
KR100564130B1 (ko) 2006-03-27
EP1815845A2 (en) 2007-08-08
EP1815845A3 (en) 2008-08-06
US20020164290A1 (en) 2002-11-07
EP1014944A2 (en) 2000-07-05
HUP0001914A2 (hu) 2000-10-28
KR20000070863A (ko) 2000-11-25
HUP0001914A3 (en) 2001-12-28
AU724765B2 (en) 2000-09-28
JP2001511179A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
HK1030357A1 (en) Biocompatible compounds for pharmaceutical drug delivery systems
GB9425160D0 (en) Medicaments
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
NZ262679A (en) Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
ATE99941T1 (de) Medikamente enthaltend salmeterol und fluticason.
GEP20002253B (en) Pharmaceutical Aerosol Formulation, Proportioning Inhalator and Method for Treatment of Respiratory Diseases
BG105033A (en) Pharmaceutical formulations for aerosols with two or more active substances
AU2001236207A1 (en) Powder formulation
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
MY108748A (en) Medicaments
BR9915095A (pt) Composição farmacêutica ministrável em aerosol
HUT68498A (en) L-dopa ester compositions and process to prepare them
IL101056A (en) Composition for nasal treatment
NZ264487A (en) Tetracycline based prodrug conjugate, pharmaceutical compositions thereof
AU644094B2 (en) Medicaments
MY130946A (en) Medicinal inhalation aerosol formulations containing budesonide
MY111155A (en) Medicaments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees